川芎嗪治疗新生儿缺氧缺血性脑病临床研究

目的探讨川芎嗪治疗新生儿缺氧缺血性脑病的疗效和安全性。方法将42例缺氧缺血性脑病新生儿随机分为研究组(基本治疗 川芎嗪治疗)23例,对照组(基本治疗)19例,同时选取10例健康儿为健康组。对三组患儿治疗前后一氧化氮、丙二醛、神经元特异性烯醇化酶、血钙、新生儿神经行为量表评分变化进行比较分析。结果入院1～2d研究组与对照组血钙无明显差异(t=0.893,P>0.05),且均低于健康组(t=4.866,4.803,P<0.05);10～11d后,治疗组上升明显高于对照组(t=2.341,P<0.05);血浆一氧化氮、丙二醛治疗前研究组与对照组无明显差异,研究组治疗后较治疗前明显下降,与对照组比较差异显著(t=3.76,2.13,P<0.05);研究组与对照组治疗前神经元特异性烯醇化酶无显著差异(t=0.243,P>0.05),两组较健康组高(t=6.09,5077,P<0.01),研究组治疗后较治疗前显著降低(t=9.15,P<0.01),对照组治疗前与治疗后无显著差异(t=1.839,P>0.05);研究组与对照组治疗前新生儿神经行为量表评分无显著差异,治疗后研究组较对照组评分差异明显(P<0.05)。结论川芎嗪可通过阻止钙内流,减少自由基,对缺氧缺血性脑病新生儿脑组织具有保护作用。

Clinical study on the tetramethylphylpyrazine in the treatment of neonatal hypoxic-ischemic encephalopathy

Objective To explore the curative effects and safety of the tetramethylphylpyrazine(TMPZ) in the treatment of neonates with hypoxic-ischemic encephalopathy(HIE). Methods 42 neonates with HIE were randomly divided into research group(n = 23, basicc treatment combined with TMPZ) and control group(n=19, single basic treatment) , and 10 healthy neonates selected as healthy group. Before and after treatment, comparative analyses of nitric oxide (NO), malondialdehyde (MDA), Neuron-specific enolase (NSE),serum calcium and the scores of Neonatal Neuro-Behavior Assessment Scale(NNBAS) were conducted among the 3 groups. Results In the 1st and 2nd days of admission, serum calcium of the research and control groups had no difference(P>0. 05) and both were lower than the healthy group(P<0. 05); after 10~11 days, serum calcium was significantly higher in the research than that in the control group(P<0. 05); before treatment there were no obvious differences in plasma NO and MDA between the research group and control group, the NO and MDA of post-treatment were significantly lower than those of pre-treatment and had significant difference from the control group(P<0. 05); before treatment, the NSE of the research and control groups had no significant difference(P>0. 05) and both were higher than the healthy group(P<0. 01), that of the research was significantly lower after treatment than before treat-ment(P<0. 01) and that of the control had no obvious difference(P>0. 05) ; the scores of the NNBAS had no obvious difference before treatment and did significant difference after treatment(P<0. 05) between the research and control groups. Conclusion The TMPZ can protect brain tissue of neonates with the HIE via preventing serum calcium into cell and decreasing free radical.